BELLEVUE, WA, Feb. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. , a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced the launch of its new corporate website at www.oncothyreon.com.
“We are excited about our new corporate identity and pleased to launch this updated website, which provides additional information about our product pipeline and new services for the investment community,” said Robert L. Kirkman, M.D., President and CEO of Oncothyreon.
Email Alerts
Those wishing to receive direct notification of Oncothyreon’s news releases, webcasts, events and other information may register online at the Oncothyreon website by visiting the “News & Events” page under the “Email Alerts” tab. Please contact Oncothyreon’s investor relations department at ir@oncothyreon.com with any questions about the new site.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
CONTACT: Investor and Media Relations Contact: Julie Rathbun, Rathbun
Communications, (206) 769-9219, ir@oncothyreon.com
